Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies.
Saved in:
| Title: | Enabling next-generation engineered TCR-T therapies based on high-throughput TCR discovery from diagnostic tumor biopsies. |
|---|---|
| Authors: | Kuilman T; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands. thomas.kuilman@astrazeneca.com., Schrikkema DS; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Gadiot J; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Gomez-Eerland R; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Bies L; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Walker J; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Spaapen RM; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Kok H; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Houg D; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Viyacheva M; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Claassen YB; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Saornil M; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Krijgsman O; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Stringer B; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Ding H; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Geleijnse A; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Meinema AC; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Weissbrich B; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Lancee M; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Engele CG; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Sabatino M; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Chen PL; Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Tsai KY; Department of Pathology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., Mulé JJ; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA.; Department of Immunology and Radiation Oncology Program, Moffitt Cancer Center, Tampa, FL, USA., Sondak VK; Department of Cutaneous Oncology, Moffitt Cancer Center, Tampa, FL, USA., van den Bulk J; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands.; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., de Miranda NF; Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands., Jedema I; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands., Haanen JG; Division of Molecular Oncology & Immunology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Division of Medical Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Clinical Oncology, Leiden University Medical Center, Leiden, The Netherlands., van Heijst JWJ; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Schumacher TN; Division of Molecular Oncology & Immunology, Oncode Institute, The Netherlands Cancer Institute, Amsterdam, The Netherlands.; Department of Hematology, Leiden University Medical Center, Leiden, The Netherlands., Linnemann C; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands., Bendle GM; Neogene Therapeutics, A member of the AstraZeneca Group, Amsterdam, The Netherlands. gavin.bendle@astrazeneca.com. |
| Source: | Nature communications [Nat Commun] 2025 Jan 14; Vol. 16 (1), pp. 649. Date of Electronic Publication: 2025 Jan 14. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Nature Pub. Group Country of Publication: England NLM ID: 101528555 Publication Model: Electronic Cited Medium: Internet ISSN: 2041-1723 (Electronic) Linking ISSN: 20411723 NLM ISO Abbreviation: Nat Commun Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2041-1723 |
|---|---|
| DOI: | 10.1038/s41467-024-55420-6 |
